title: Ghrelin Protects against the Detrimental Consequences of Porphyromonas gingivalis-Induced Akt Inactivation through S-Nitrosylation on Salivary Mucin Synthesis.
abstract: Disturbances in nitric oxide synthase isozyme system and the impairment in salivary mucin synthesis are well-recognized features associated with oral mucosal inflammatory responses to periodontopathic bacterium, P. gingivalis. In this study, using rat sublingual gland acinar cells, we report that P. gingivalis LPS-induced impairment in mucin synthesis and associated suppression in Akt kinase activity were accompanied by a decrease in constitutive nitric oxide synthase (cNOS) activity and an induction in inducible nitric oxide synthase (iNOS) expression. The LPS effect on Akt inactivation was manifested in the kinase S-nitrosylation and a decrease in its phosphorylation at Ser(473). Further, we demonstrate that a peptide hormone, ghrelin, countered the LPS-induced impairment in mucin synthesis. This effect of ghrelin was reflected in the suppression of iNOS and the increase in Akt activation, associated with the loss in S-nitrosylation and the increase in phosphorylation, as well as cNOS activation through phosphorylation. Our findings suggest that induction in iNOS expression by P. gingivalis-LPS leads to Akt kinase inactivation through S-nitrosylation that detrimentally impacts cNOS activation through phosphorylation as well as mucin synthesis. We also show that the countering effect of ghrelin on P. gingivalis-induced impairment in mucin synthesis is associated with Akt activation through phosphorylation.
authors: Research Center, University of Medicine and Dentistry of New Jersey, P.O. Box 1709, Newark, NJ 07103-2400, USA.
authors: Bronislaw L
authors: BL
authors: Slomiany
authors: Amalia
authors: A
authors: Slomiany
references: Inflammopharmacology. 2006 Dec;14(5-6):250-5
references: 17093905
references: J Biol Chem. 2007 May 11;282(19):13977-83
references: 17376775
references: Gen Pharmacol. 1996 Jul;27(5):761-71
references: 8842677
references: Endocrinology. 2008 Aug;149(8):4183-92
references: 18450953
references: Clin Microbiol Infect. 2001 Apr;7(4):213-7
references: 11422244
references: Biochim Biophys Acta. 2004 Mar 11;1697(1-2):3-16
references: 15023346
references: Physiol Rev. 2005 Apr;85(2):495-522
references: 15788704
references: J Signal Transduct. 2010;2010:643642
references: 21637354
references: J Biol Chem. 2005 Mar 4;280(9):7511-8
references: 15632167
references: Curr Drug Targets Inflamm Allergy. 2005 Aug;4(4):471-9
references: 16101524
references: J Biol Chem. 2003 Jan 24;278(4):2118-23
references: 12431978
references: Biochem J. 1997 Dec 1;328 ( Pt 2):363-9
references: 9371689
references: Anal Biochem. 1982 Oct;126(1):131-8
references: 7181105
references: Inflammopharmacology. 2010 Jun;18(3):119-25
references: 20155328
references: Mol Cell. 2002 Jun;9(6):1227-40
references: 12086620
references: Diabetes. 2005 Apr;54(4):959-67
references: 15793233
references: Nat Cell Biol. 2001 Feb;3(2):193-7
references: 11175752
references: Am J Physiol Endocrinol Metab. 2006 Sep;291(3):E476-82
references: 16638822
references: Kidney Int. 2007 Feb;71(4):290-7
references: 17200681
references: J Clin Periodontol. 2000 Oct;27(10):722-32
references: 11034118
references: Surgery. 2008 Mar;143(3):334-42
references: 18291254
references: Clin Chem. 2005 Jun;51(6):997-1006
references: 15790755
references: Biochem Biophys Res Commun. 2002 Oct 11;297(5):1149-53
references: 12372406
references: Int J Biomed Sci. 2010 Mar;6(1):37-44
references: 23675174
references: J Physiol Pharmacol. 2002 Mar;53(1):21-38
references: 11939716
references: PLoS One. 2009;4(3):e4686
references: 19262695
references: J Physiol Pharmacol. 2003 Mar;54(1):3-15
references: 12674215
references: Crit Rev Oral Biol Med. 2002;13(2):132-42
references: 12097356